Message from the CEO
Since our May 2013 newsletter we have made ten material announcements to the market with strong positive impact on our diagnostic, therapeutic and consumer health businesses. We have also released our annual report for the 2013 financial year recently showing 300% increase in operational revenue and 20% reduction in loss, and our share price is up more than 100% this year.
In late May we settled the acquisition of Advangen Inc, Japan, taking control of the global rights to the FGF-5 inhibitor products for hair growth. Since then, we have increased sales in Australia and signed a major Japanese distribution agreement for 30,000 units of our products, representing over 40% of our expected annual revenue in that region. This momentum should continue as we pursue other markets and expect new territories signed up in 2014.
To view Newsletter please download PDF below:
